Key facts
- Rivia (Enterprise Systems)’s last known valuation is $67.0M (Mar 2026).
- It has raised $18.8M; the latest was Early Stage VC ($15.4M) in Mar 2026.
- Notable investors include Venture Kick, Speedinvest, Earlybird Venture Capital, Amino Collective, Defiant Capital Group — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Rivia (Enterprise Systems)
- ·The full record, as it builds
Funding rounds
No funding rounds for Rivia (Enterprise Systems) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Rivia (Enterprise Systems)
Developer of clinical trial data integration and analytics software designed for transforming fragmented research data into structured intelligence for analysis and decision-making. The company integrates multi-source data, standardizes formats, applies AI-driven quality checks and analytics, and enables visualization and querying, enabling biopharma organizations to improve trial oversight, data consistency, and decision-making.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2022
- Employees
- 20
- Website
- rivia.com/
- Ownership
- Privately Held (backing)
Rivia (Enterprise Systems) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Rivia (Enterprise Systems) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Rivia (Enterprise Systems) in its N-PORT filings yet. We sweep new filings monthly.